Glucotrack, Inc. Announces Reverse Stock SplitBusiness Wire · 4 days ago
Glucotrack, Inc. Announces Pricing of $3 Million Public OfferingGuruFocus · Sep 24, 2026
Glucotrack, Inc. Announces Pricing of $3 Million Public OfferingBusiness Wire · Sep 24, 2026
Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving PremarketBenzinga · Sep 24, 2026
Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development PrioritiesBusiness Wire · Sep 23, 2026
Lōkahi Therapeutics™ Continues ai² Pipeline™ Division Collaboration with The University of Alabama to Advance Asset Evaluation and Biopharma TalentGuruFocus · Sep 18, 2026GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing the GlucoTrack CBGM, a long-term implantable continuous blood glucose monitoring system for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.